LIPELLA PHARMACEUTICALS INC. (LIPO) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US53630L2097

Price
0.00 USD
Market cap
524.09 USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

LIPELLA PHARMACEUTICALS INC. financials

Fiscal year2024
Revenue536,357.00 USD
Operating income-5.08 m USD
EBIT-5.08 m USD
Net income-5.02 m USD
Diluted EPS – continuing operations-4.79 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About LIPELLA PHARMACEUTICALS INC.

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.